Skip to Content

'
Susan M. O'Brien, MD

Present Title & Affiliation

Primary Appointment

Ashbel Smith Professor, Department of Leukemia, Division of Cancer Medicine, UT MD Anderson Cancer Center, Houston, TX

Education & Training

Postgraduate Training

1/1985-1/1987 Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX

Experience/Service

Academic Appointments

Associate Professor, Department of Leukemia, Division of Medicine, UT MD Anderson Cancer Center, Houston, TX, 1995-1999
Assistant Professor, UT MD Anderson Cancer Center, Houston, TX, 1989-1995
Instructor, UT MD Anderson Cancer Center, Houston, TX, 1988-1989
Faculty Associate, UT MD Anderson Cancer Center, Houston, TX, 1987-1988
Instructor, UCLA School of Medicine, San Fernando Valley Program, Sepulveda, CA, 1984-1985
Internist, University of Southern California, Student Health Service, Los Angeles, CA, 1984-1985
Instructor, Section of Hematology/Oncology, University of Medicine & Dentistry of New Jersey, Newark, NJ, 1983-1984

Institutional Committee Activities

Member, Molecular Testing Evaluation Committee, 9/2010-present
Chair, Institutional Review Board (IRB)1, 2007-present
Vice-Chairperson, Institutional Review Board (IRB)1, 2003-2006
Past Chairperson, Faculty Senate, 2002-2003
Chairperson, Faculty Senate, 2001-2002
Chair, Study Section Review Committee for Clinical, Translational, Population-Based Project, 2000-2001
Chairperson-Elect, Faculty Senate, 2000-2001
Member, Chairman of Pediatrics Division Search Committee, 1999-2000
Member, Chairman of Department of Hematopathology Search Committee, 1999-2000
Member, President's Advisory Board and Clinical Council, 1999-2000
Member, Executive Committee Faculty Senate, 1998-2003
Member, IRB Committee, 1997-present
Member, Standing Committee for Clinical Affairs, 1997-present
Chairperson, Clinical Research Committee, 1997-2001
Chairman, Hematology Mortality Conference, 1988-2000

Honors and Awards

2010-2011 Houston's Top Doctors for Cancer, Castle Connolly Medical Ltd.
2010 Houston's Top Doctors, H Texas Magazine
2009-2010 Best Doctors in America, Best Doctors, Inc.
2009-2010 Texas Monthly, Top Doctors, Texas Monthly
2009-2010 Texas Super Doctors 2009, Texas Monthly
2009 4th Annual Melvin L. Samuels Award for Excellence in Patient Care, UT MD Anderson Cancer Center
2006 Houston's Top Doctors, H Texas Magazine
2003-2005 America's Top Physicians, Consumer Research Council of America
2002-2004 Best Doctors in America, Best Doctors, Inc.
2002 Houston's Top Doctors, Inside Houston Magazine
1998 Houston's Top Doctors, Inside Houston Magazine
1996-1999 Best Doctors in America, Best Doctors, Inc.

Selected Publications

Peer-Reviewed Original Research Articles

1. Schweighofer CD, Coombes KR, Majewski T, Barron LL, Lerner S, Sargent RL, O'Brien S, Ferrajoli A, Wierda WG, Czerniak BA, Medeiros LJ, Keating MJ, Abruzzo LV. Genomic Variation by Whole-Genome SNP Mapping Arrays Predicts Time-to-Event Outcome in Patients with Chronic Lymphocytic Leukemia: A Comparison of CLL and HapMap Genotypes. J Mol Diagn. e-Pub 12/2012. PMID: 23273604.
2. Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, O'Brien S. Phase 1 study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma 53(11):2136-42, 11/2012. e-Pub 6/2012. PMID: 22475052.
3. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Garcia-Manero G, Shan J, Pierce S, Cortes J, O'Brien S. Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma 51(3):475-80, 3/2010. PMID: 20078325.
4. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28(3):392-7, 1/2010. PMCID: PMC2815701.
5. Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 115(3):489-95, 1/2010. PMCID: PMC2810983.
6. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28(3):398-404, 1/2010. PMCID: PMC2815702.
7. Thomas DA, Kantarjian HM, Stock W, Heffner LT, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Pierce S, Lu B, Deitcher SR, O'Brien S. Phase 1 multi-center study of vincristine sulfate liposomes injection (VSLI) and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer 115(23):5490-8, 12/2009. PMID: 19708032.
8. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, Chanan-Khan AA, Seymour JF, Gribben J, Itri LM, Rai KR. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized phase 3 trial of fludarabine plus cyclophosphamide with or without oblimersen: the oblimersen CLL study group. J Clin Oncol 27(31):5208-12, 11/2009. PMID: 19738118.
9. Jain N, Wierda W, Ferrajoli A, Wong F, Lerner S, Keating M, O'Brien S. A phase 2 study of yttrium-90 ibritumomab tiuxetan (zevelin) in patients with chronic lymphocytic leukemia. Cancer 115(19):4533-9, 10/2009. PMID: 19637351.
10. O'Brien S, Berman E, Borghaei H, Deangelo DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Moore JO, Mughal T, Pinilla-Ibarz J, Radich JP, Shah Md NP, Shami PJ, Smith BD, Snyder DS, Tallman MS, Talpaz M, Wetzler M, National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw 7(9):984-1023, 10/2009. PMID: 19878641.
11. Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 113(25):6330-37, 6/2009. PMID: 18703706.
12. Garg R, Kantarjian H, Thomas D, Faderl S, Ravandi F, Lovshe D, Pierce S, O'Brien S. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorbucin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy. Cancer 115(10):2147-54, 5/2009. PMID: 19298009.
13. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 27(10):1637-43, 4/2009. PMID: 19224852.
14. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113(2):299-305, 1/2009. PMID: 18931344.
15. Quintás-Cardama A, O'Brien S. Targeted therapy for chronic lymphocytic leukemia. Target Oncol 4(1):11-21, 1/2009. PMID: 19343298.
16. O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113(11):3186-91, 12/2008. PMID: 18846563.
17. O'Brien S. New Agents in the Treatment of CLL. Hematology Am Soc Hematol Educ Program:457-64, 2008. PMID: 19074126.

Last updated: 2/4/2013